Approval Alert | Mirvetuximab Soravtansine Folate Receptor-α-Positive Platinum-Resistant Ovarian Cancer

In November 2022, mirvetuximab soravtansine-gynx was given accelerated approval by the FDA for the treatment of patients with folate receptor-α-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer cancer who have been treated with 1 to 3 lines of prior therapy.

Ursula A. Matulonis, MD, Reviews Additional Trials Investigating Mirvetuximab Soravtansine in FR-α–Positive Platinum-Resistant Ovarian Cancer
Video
Ursula A. Matulonis, MD, Reviews Additional Trials Investigating Mirvetuximab Soravtansine in FR-α–Positive Platinum-Resistant Ovarian Cancer
Nov 22, 2022 1:00 PM
Ursula A. Matulonis, MD, discussued studies are being conducted assessing the use of mirvetuximab soravtansine in patients with folate receptor-α–positive platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, Highlights How Mirvetuximab Soravtansine FDA Approval in FR-α+ Platinum-Resistant Ovarian Cancer Could Impact Treatment
Video
Ursula A. Matulonis, MD, Highlights How Mirvetuximab Soravtansine FDA Approval in FR-α+ Platinum-Resistant Ovarian Cancer Could Impact Treatment
Nov 16, 2022 9:00 PM
Ursula A. Matulonis, MD, indicated that acknowledgement of external targets such as FR-α could lead to success with antibody-drug conjugates in platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, on the Approval of Mirvetuximab Soravtansine in FR-α–Positive Platinum-Resistant Ovarian Cancer
Video
Ursula A. Matulonis, MD, on the Approval of Mirvetuximab Soravtansine in FR-α–Positive Platinum-Resistant Ovarian Cancer
Nov 15, 2022 9:00 PM
Ursula A. Matulonis, MD, spoke about the phase 3 SORAYA trial and how it helped lead to the approval of mirvetuximab soravtansine in folate receptor-α–positive platinum-resistant ovarian cancer.
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine for Subset of Platinum-Resistant Ovarian Cancer
Article
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine for Subset of Platinum-Resistant Ovarian Cancer
Nov 14, 2022 10:53 PM
The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.